白蛋白结合型紫杉醇联合铂类治疗复发转移性头颈部鳞癌的临床效果及对肿瘤标志物水平的影响  

Clinical effect of Albumin-bound Paclitaxel combined with Platinum in the treatment of recurrent and metastatic head and neck squamous cell carcinoma and the level of tumor markers

作　　者：王娟 曹剑锋 何云华 单桂芹 葛方红 WANG Juan;CAO Jianfeng;HE Yunhua;SHAN Guiqin;GE Fanghong(Department of Oncology,Tongzhou District People′s Hospital of Nantong City,Jiangsu Province,Nantong 226300,China;Department of Radiotherapy,Cancer Hospital Affiliated to Nantong University,Jiangsu Province,Nantong 226361,China)

机构地区：[1]江苏省南通市通州区人民医院肿瘤科,江苏南通226300 [2]南通大学附属肿瘤医院放疗科,江苏南通226361

出　　处：《中国当代医药》2022年第18期18-21,共4页China Modern Medicine

基　　金：江苏省南通市卫生健康委员会科研课题(QA2019053)。

摘　　要：目的研究白蛋白结合型紫杉醇联合铂类治疗复发转移性头颈部鳞癌的临床效果及对肿瘤标志物水平的影响。方法选取2019年6月至2020年12月南通市通州区人民医院肿瘤科及南通大学附属肿瘤医院放疗科收治的60例复发转移性头颈部鳞癌患者作为研究对象,采用抛硬币法将其随机分为对照组与观察组,每组各30例。对照组患者采用紫杉醇联合铂类化疗,观察组患者采用白蛋白结合型紫杉醇联合铂类化疗。比较两组患者的近期疗效、治疗前后的血清肿瘤标志物[血清鳞状细胞癌相关抗原(SCC)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)]水平及不良反应发生率。结果观察组患者的疾病控制率(DCR)为80.00%,高于对照组的53.33%,差异有统计学意义(P<0.05)。两组患者治疗后的SCC、CEA、VEGF水平均低于治疗前,差异有统计学意义(P<0.001)。观察组患者治疗后的SCC、CEA、VEGF水平均低于对照组,差异有统计学意义(P<0.05)。观察组患者的不良反应总发生率为50.00%,低于对照组的76.67%,差异有统计学意义(P<0.05)。结论白蛋白结合型紫杉醇联合铂类用于复发转移性头颈部鳞癌中近期疗效确切,可降低肿瘤标志物水平,不良反应可控,值得推广。Objective To study the effect of Albumin-bound Paclitaxel combined with Platinum on the clinical efficacy and tumor marker levels of recurrent and metastatic head and neck squamous cell carcinoma.Methods A total of 60 patients with recurrent and metastatic head and neck squamous cell carcinoma admitted to Tongzhou District People′s Hospital of Nantong City and Cancer Hospital Affiliated to Nantong University from June 2019 to December 2020 were selected as the research objects and randomly divided into the control group and the observation group by coin flipping,with 30 cases in each group.The control group was treated with Paclitaxel combined with Platinum chemotherapy,and the observation group was treated with Albumin-bound Paclitaxel combined with Platinum chemotherapy.The short-term efficacy,the levels of tumor markers serum(squamous cell carcinoma-associated antigen[SCC],carcinoembryonic antigen[CEA],and vascular endothelial growth factor[VEGF])before and after treatment and the incidence of adverse reactions were compared.Results The disease control rate(DCR)of the observation group was 80.00%,which was higher than that of the control group(53.33%),and the difference was statistically significant(P<0.05).After treatment,the levels of SCC,CEA and VEGF in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the levels of SCC,CEA and VEGF in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.001).The incidence of adverse reactions in the observation group was 50.00%,which was lower than 76.67%in the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of Albumin-bound Paclitaxel and Platinum for recurrent and metastatic head and neck squamous cell carcinoma has a definite short-term curative effect,which can reduce the level of tumor markers,and the adverse reactions are controllable.It is worthy of promotion.

关 键 词：白蛋白结合型紫杉醇 铂类 复发转移性 头颈部鳞癌 肿瘤标志物 

分 类 号：R739.91[医药卫生—肿瘤]